Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Launched by PHARMBIO KOREA CO., LTD. · Jan 27, 2010
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female over 18
- • Patients with respiratory tract infection who are receiving an oral or injection antibiotics.
- • Signed informed consent form prior to inclusion in the study.
- • Patients who begin receiving antibiotics within 48 hours before enrollment in this study.
- Exclusion Criteria:
- • Diagnosed Clostridium difficile colitis within the last 3 months
- • Patients with tube feeding, ileostomy or colostomy
- • Patients with basal diarrheal disease; acute enteritis, chronic diarrhea such as inflammatory bowel disease (IBD) etc, radiation enteritis, ischemic colitis and diarrhea caused by carcinoids etc.
- • Patients receiving other probiotics during the last 15 days
- • Patients treated with immunosuppressant drugs or immune deficiency patients
- • Patients with radiotherapy and chemotherapy treatment for cancer.
- • Patients treated with antidiarrheal, antispasmodic or motility agents for other diseases.
- • Pregnant/Lactating women
- • Patients with gastrointestinal (GI) surgery during the last 3 months.
- • A history of hypersensitivity to cephalosporins, penicillin or clavulanic acid.
- • Patients with verified diabetic autonomic neuropathy.
- • Patients with organ transplants.
- • Patients with underlying conditions or diseases which, in the opinion of the investigator, are unsuitable for inclusion.
About Pharmbio Korea Co., Ltd.
Pharmbio Korea Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong focus on improving patient outcomes, Pharmbio Korea leverages advanced biotechnology and rigorous clinical trial methodologies to bring cutting-edge treatments to market. The company is committed to maintaining the highest standards of quality and compliance in its operations, fostering collaborations with healthcare professionals and regulatory bodies to ensure the safety and efficacy of its products. Through its dedicated team of experts and a robust pipeline, Pharmbio Korea aims to address unmet medical needs and contribute to the advancement of global healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Sung-Ae Jung, MD, PhD
Principal Investigator
Ewha Womans University Mokdong Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials